Evidence map›Paper›PMID 33482143›Full record

ArticleThe Lancet. Infectious diseases2021

Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results.

Jenny M MacLennan, Charlene M C Rodrigues, Holly B Bratcher, Aiswarya Lekshmi, Adam Finn, Jenny Oliver, Mandy Wootton, Samantha Ray, Claire Cameron, Andrew Smith and 24 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Meningococcal carriage in children and young adults: a cross-sectional and longitudinal study, Iceland, 2019 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Article
  12. Review
  13. Article
  14. Prevalence and persistence ofEpidemiology and infection · 2023
    Article
  15. Article
  16. Article
  17. Prevalence and Characteristics of Carriage ofOpen forum infectious diseases · 2022
    Article
  18. Article
  19. The Host-Pathogen Interactions and Epicellular Lifestyle ofFrontiers in cellular and infection microbiology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 18 institutions in 1 country.

Jenny M MacLennanDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Charlene M C RodriguesDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Holly B BratcherDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Aiswarya LekshmiMeningococcal Reference Unit, Public Health England, Manchester Public Health Laboratory, Manchester Royal Infirmary, Manchester, UK.
Adam FinnSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Jenny OliverSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Mandy WoottonDivision of Public Health Wales, Temple of Peace and Health, Cardiff, UK.
Samantha RayDivision of Public Health Wales, Temple of Peace and Health, Cardiff, UK.
Claire CameronNHS National Services Scotland, Health Protection Scotland, Glasgow, UK.
Andrew SmithGlasgow Dental School, University of Glasgow, UK; Scottish Microbiology Reference Laboratory, NHS Greater Glasgow & Clyde, Glasgow, UK.
Paul T HeathSt George's Vaccine Institute, Institute of Infection & Immunity, St George's University of London, London, UK.
Angela BartolfSt George's Vaccine Institute, Institute of Infection & Immunity, St George's University of London, London, UK.
Tracey NolanResearch and Development Department, Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, UK.
Stephen HughesCentral Manchester University Hospitals, NHS Foundation Trust, Manchester, UK.
Anu VargheseCentral Manchester University Hospitals, NHS Foundation Trust, Manchester, UK.
Matthew D SnapeOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK.
Richard SewellOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK.
Richard CunninghamDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Alison StoltonMicrobiology Department, University Hospitals Plymouth NHS Trust, UK.
Carole KayLancashire and South Cumbria NHS Foundation Trust, Preston, Lancashire, UK.
Karen PalmerLancashire and South Cumbria NHS Foundation Trust, Preston, Lancashire, UK.
David BaxterStockport NHS Foundation Trust, Stepping Hill Hospital, Stockport, UK.
Debbie SuggittStockport NHS Foundation Trust, Stepping Hill Hospital, Stockport, UK.
Christos S ZipitisManchester Academic Health Science Centre, University of Manchester, Manchester, UK; Department of Paediatrics, Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, UK.
Nicola PembertonClinical Trials Department, Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, UK.
Keith A JolleyDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
James E BrayDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Odile B HarrisonDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK.
Shamez N LadhaniPaediatric Infectious Diseases Research Group, St George's University of London, London, UK; Immunisation and Countermeasures Division, Public Health England, London, UK.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK.
Raymond BorrowMeningococcal Reference Unit, Public Health England, Manchester Public Health Laboratory, Manchester Royal Infirmary, Manchester, UK.
Stephen J GrayMeningococcal Reference Unit, Public Health England, Manchester Public Health Laboratory, Manchester Royal Infirmary, Manchester, UK.
Caroline TrotterDisease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
Martin C J MaidenDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK. Electronic address: martin.maiden@zoo.ox.ac.uk.
Medawar Building for Pathogen Research · GBUniversity of Oxford · GBSt George's, University of London · GBLancashire Care NHS Foundation Trust · GBManchester Royal Infirmary · GBManchester University NHS Foundation Trust · GBPublic Health Wales · GBStockport NHS Foundation Trust · GBUniversity of Bristol · GBHealth Protection Scotland · GBMaidstone and Tunbridge Wells NHS Trust · GBManchester Academic Health Science Centre · GBNational Institute for Health Research · GBNHS Greater Glasgow and Clyde · GBPublic Health England · GBUniversity Hospitals Plymouth NHS Trust · GBUniversity of Cambridge · GBWrightington, Wigan and Leigh NHS Foundation Trust · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundThe incidence of invasive meningococcal disease in the UK decreased by approximately four times from 1999 to 2014, with reductions in serogroup C and serogroup B disease. Lower serogroup C invasive meningococcal disease incidence was attributable to implementation of the meningococcal serogroup C conjugate vaccine in 1999, through direct and indirect protection, but no vaccine was implemented against serogroup B disease. UK Meningococcal Carriage surveys 1-3 (UKMenCar1-3), conducted in 1999, 2000, and 2001, were essential for understanding the impact of vaccination. To investigate the decline in invasive meningococcal disease incidence, we did a large oropharyngeal carriage survey in 2014-15, immediately before the changes to meningococcal vaccines in the UK national immunisation schedule.

methodsUKMenCar4 was a cross-sectional survey in adolescents aged 15-19 years who were enrolled from schools and colleges geographically local to one of 11 UK sampling centres between Sept 1, 2014, and March 30, 2015. Participants provided an oropharyngeal swab sample and completed a questionnaire on risk factors for carriage, including social behaviours. Samples were cultured for putative Neisseria spp, which were characterised with serogrouping and whole-genome sequencing. Data from this study were compared with the results from the UKMenCar1-3 surveys (1999-2001).

findingsFrom the 19 641 participants (11 332 female, 8242 male, 67 not stated) in UKMenCar4 with culturable swabs and completed risk-factor questionnaires, 1420 meningococci were isolated, with a carriage prevalence of 7·23% (95% CI 6·88-7·60). Carriage prevalence was substantially lower in UKMenCar4 than in the previous surveys: carriage prevalence was 16·6% (95% CI 15·89-17·22; 2306/13 901) in UKMenCar1 (1999), 17·6% (17·05-18·22; 2873/16 295) in UKMenCar2 (2000), and 18·7% (18·12-19·27; 3283/17 569) in UKMenCar3 (2001). Carriage prevalence was lower for all serogroups in UKMenCar4 than in UKMenCar1-3, except for serogroup Y, which was unchanged. The prevalence of carriage-promoting social behaviours decreased from 1999 to 2014-15, with individuals reporting regular cigarette smoking decreasing from 2932 (21·5%) of 13 650 to 2202 (11·2%) of 19 641, kissing in the past week from 6127 (44·8%) of 13 679 to 7320 (37·3%) of 19 641, and attendance at pubs and nightclubs in the past week from 8436 (62·1%) of 13 594 to 7662 (39·0%) of 19 641 (all p<0·0001).

interpretationWe show that meningococcal carriage prevalence in adolescents sampled nationally during a low incidence period (2014-15) was less than half of that in an equivalent population during a high incidence period (1999-2001). Disease and carriage caused by serogroup C was well controlled by ongoing vaccination. The prevalence of behaviours associated with carriage declined, suggesting that public health policies aimed at influencing behaviour might have further reduced disease.

fundingWellcome Trust, UK Department of Health, and National Institute for Health Research.

Indexed as

AdolescentCarrier StateCross-Sectional StudiesFemaleHumansIncidenceMaleMeningococcal InfectionsMeningococcal VaccinesNeisseria meningitidisNeisseria meningitidis, Serogroup CPrevalenceRisk FactorsSerogroupUnited KingdomVaccinationMeningococcal Vaccinesserogroup C meningococcal conjugate vaccine

Identifiers

PMID33482143
PMCPMC8064914
OpenAlexW3124733160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.